Altered macrophage differentiation and immune dysfunction in tumor development.

Tumors require a constant influx of myelomonocytic cells to support the angiogenesis and stroma remodeling needed for their growth. This is mediated by tumor-derived factors, which cause sustained myelopoiesis and the accumulation and functional differentiation of myelomonocytic cells, most of which are macrophages, at the tumor site. An important side effect of the accumulation and functional differentiation of these cells is that they can induce lymphocyte dysfunction. A complete understanding of the complex interplay between neoplastic and myelomonocytic cells might offer novel targets for therapeutic intervention aimed at depriving tumor cells of important growth support and enhancing the antitumor immune response.

[1]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[2]  H. Claman,et al.  Natural suppressor cells. , 1989, Progress in clinical and biological research.

[3]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[4]  R. Ronca,et al.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. , 2000, Blood.

[5]  A. Frey,et al.  Tumor-Infiltrating Macrophages Induce Apoptosis in Activated CD8+ T Cells by a Mechanism Requiring Cell Contact and Mediated by Both the Cell-Associated Form of TNF and Nitric Oxide1 , 2001, The Journal of Immunology.

[6]  M. Fresno,et al.  Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1(+))CD11b(+ )immature myeloid suppressor cells. , 2002, International immunology.

[7]  S. Signoretti,et al.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.

[8]  Paolo Serafini,et al.  Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. , 2006, The Journal of clinical investigation.

[9]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[10]  C. Divino,et al.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. , 2006, Cancer research.

[11]  A. Sharpe,et al.  CD80+Gr-1+ Myeloid Cells Inhibit Development of Antifungal Th1 Immunity in Mice with Candidiasis1 , 2002, The Journal of Immunology.

[12]  H. Schreiber,et al.  Inhibition of tumor growth by elimination of granulocytes , 1995, The Journal of experimental medicine.

[13]  G. Lesinski,et al.  The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse , 2003 .

[14]  J. Berzofsky,et al.  Mice infected with Schistosoma mansoni develop a novel non-T-lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor. , 2001, Microbes and infection.

[15]  J. Berzofsky,et al.  Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance , 2003, The Journal of Experimental Medicine.

[16]  F. Balkwill.  Chemokine biology in cancer. , 2003, Seminars in immunology.

[17]  Ira Mellman,et al.  Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.

[18]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[19]  D. Gabrilovich,et al.  Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells1 , 2001, The Journal of Immunology.

[20]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[21]  U. Förstermann,et al.  Regulation of the Expression of Inducible Nitric Oxide Synthase , 2003, Biological chemistry.

[22]  A. Richmond.  Nf-kappa B, chemokine gene transcription and tumour growth. , 2002, Nature reviews. Immunology.

[23]  O. Levy,et al.  TCR ζ Down-Regulation under Chronic Inflammation Is Mediated by Myeloid Suppressor Cells Differentially Distributed between Various Lymphatic Organs1 , 2006, The Journal of Immunology.

[24]  J. Brayer,et al.  Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.

[25]  P. Sinha,et al.  Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1 , 2005, The Journal of Immunology.

[26]  M. Karin,et al.  The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer , 2004 .

[27]  O. Finn,et al.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. , 2001, Cancer research.

[28]  D. Gabrilovich,et al.  Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells1 , 2005, The Journal of Immunology.

[29]  P. Allavena,et al.  Defective Expression of the Monocyte Chemotactic Protein-1 Receptor CCR2 in Macrophages Associated with Human Ovarian Carcinoma1 , 2000, The Journal of Immunology.

[30]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. , 2000, The American journal of pathology.

[31]  D. Geller,et al.  Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-κB , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Baniyash.  TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. , 2004, Nature reviews. Immunology.

[33]  J. Califano,et al.  Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function , 2006, The Journal of experimental medicine.

[34]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[35]  P. De Baetselier,et al.  Arginase-1 and Ym1 Are Markers for Murine, but Not Human, Alternatively Activated Myeloid Cells , 2005, The Journal of Immunology.

[36]  M. Karin,et al.  The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. , 2004, Cancer letters.

[37]  C. Liu,et al.  Targeting tumor-associated macrophages as a novel strategy against breast cancer. , 2006, The Journal of clinical investigation.

[38]  R. Schreiber,et al.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Silvano Sozzani,et al.  The chemokine system in diverse forms of macrophage activation and polarization. , 2004, Trends in immunology.

[40]  M Aguet,et al.  The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.

[41]  T. Saito,et al.  Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[43]  D. Herndon,et al.  Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. , 2004, Immunity.

[44]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[45]  Rinat Abramovitch,et al.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer. , 2004, Nature.

[46]  Daniele M. Gilkes,et al.  Activation of Dendritic Cells via Inhibition of Jak2/STAT3 Signaling1 , 2005, The Journal of Immunology.

[47]  D. Gabrilovich,et al.  Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species1 , 2004, The Journal of Immunology.

[48]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[49]  D. Quiceno,et al.  L-arginine availability regulates T-lymphocyte cell-cycle progression. , 2007, Blood.

[50]  J. Moulinoux,et al.  Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. , 1995, Journal of immunology.

[51]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[52]  G. Lesinski,et al.  The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. , 2003, The Journal of clinical investigation.

[53]  S. Gea,et al.  Cruzipain, a major Trypanosoma cruzi antigen, conditions the host immune response in favor of parasite , 2002, European journal of immunology.

[54]  D. Gabrilovich,et al.  Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer , 2006, Cancer Immunology, Immunotherapy.

[55]  S. Morris.  Regulation of enzymes of the urea cycle and arginine metabolism. , 2002, Annual review of nutrition.

[56]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[57]  S. Saccani,et al.  Regulation of the Chemokine Receptor CXCR4 by Hypoxia , 2003, The Journal of experimental medicine.

[58]  Alberto Mantovani,et al.  Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.

[59]  P. De Baetselier,et al.  Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. , 2006, Blood.

[60]  M. Young,et al.  Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. , 1996, Journal of immunology.

[61]  I. Buschmann,et al.  Divergent effects of GM‐CSF and TGFβ1 on bone marrow‐ derived macrophage arginase‐1 activity, MCP‐1 expression, and matrix‐metalloproteinase‐12: a potential role during arteriogenesis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[63]  P. Hwu,et al.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. , 1999, Journal of immunology.

[64]  Shulin Li,et al.  Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression. , 2006, Cancer research.

[65]  P. H. Correll,et al.  Activation of the Stem Cell-Derived Tyrosine Kinase/RON Receptor Tyrosine Kinase by Macrophage-Stimulating Protein Results in the Induction of Arginase Activity in Murine Peritoneal Macrophages1 , 2002, The Journal of Immunology.

[66]  M. Munder,et al.  Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. , 1998, Journal of immunology.

[67]  A. Gobl,et al.  Interferon Alpha Induction of Stat1 and Stat2 and Their Prognostic Significance in Carcinoid Tumors , 2001, Oncology.

[68]  A. Viola,et al.  Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers , 2005, The Journal of experimental medicine.

[69]  A. Mui,et al.  SHIP represses the generation of alternatively activated macrophages. , 2005, Immunity.

[70]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[71]  Prabir Ray,et al.  A critical role for NF-κB in Gata3 expression and TH2 differentiation in allergic airway inflammation , 2001, Nature Immunology.

[72]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[73]  Geoffrey C Gurtner,et al.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.

[74]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[75]  J. Albina,et al.  MACROPHAGE ARGINASE REGULATION BY CCAAT/ENHANCER-BINDING PROTEIN β , 2005, Shock.

[76]  M. Colombo,et al.  The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.

[77]  U. Grohmann,et al.  The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.

[78]  P. Rodriguez,et al.  T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. , 2006, Seminars in cancer biology.

[79]  T. Mcclanahan,et al.  IL-23 promotes tumour incidence and growth , 2006, Nature.

[80]  R. Ronca,et al.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. , 2000, Blood.

[81]  F. Kayaselçuk,et al.  Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. , 2006, Journal of experimental & clinical cancer research : CR.

[82]  A. Mantovani,et al.  Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. , 2005, Cancer research.

[83]  A. Harris,et al.  Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. , 2002, Cancer research.

[84]  Yuka Kanno,et al.  Signaling by IL‐12 and IL‐23 and the immunoregulatory roles of STAT4 , 2004, Immunological reviews.

[85]  Jay A. Berzofsky,et al.  NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway , 2000, Nature Immunology.

[86]  Marian Taylor,et al.  Relation of Hypoxia-inducible Factor-2α (HIF-2α) Expression in Tumor-infiltrative Macrophages to Tumor Angiogenesis and the Oxidative Thymidine Phosphorylase Pathway in Human Breast Cancer , 2002 .

[87]  S. Mocellin,et al.  Erratum: Part 1: Vaccines for solid tumours (Lancet Oncology (2004) vol. 5 (681-689)) , 2005 .

[88]  Michael Karin,et al.  NF-kappaB at the crossroads of life and death. , 2002, Nature immunology.

[89]  H. Schreiber,et al.  Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[90]  A. Visintin,et al.  Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism1 , 2002, The Journal of Immunology.

[91]  A. Sica,et al.  Macrophage polarization comes of age. , 2005, Immunity.

[92]  R. Jove,et al.  Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer , 2004, The Journal of Immunology.

[93]  A. Kolb,et al.  Suppression of T-cell functions by human granulocyte arginase. , 2006, Blood.

[94]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[95]  S. Gordon.  Alternative activation of macrophages , 2003, Nature Reviews Immunology.

[96]  Michael Karin,et al.  NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.

[97]  Simone Mocellin,et al.  Part I: Vaccines for solid tumours. , 2004, The Lancet. Oncology.

[98]  D. Harn,et al.  The Schistosome Oligosaccharide Lacto-N-neotetraose Expands Gr1+ Cells That Secrete Anti-inflammatory Cytokines and Inhibit Proliferation of Naive CD4+ Cells: A Potential Mechanism for Immune Polarization in Helminth Infections , 2001, The Journal of Immunology.

[99]  Barbara Bottazzi,et al.  Autocrine Production of IL-10 Mediates Defective IL-12 Production and NF-κB Activation in Tumor-Associated Macrophages1 , 2000, The Journal of Immunology.

[100]  S. Rosenberg,et al.  Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. , 1998, Journal of immunology.

[101]  P. De Baetselier,et al.  Nitric Oxide-Independent CTL Suppression during Tumor Progression: Association with Arginase-Producing (M2) Myeloid Cells1 , 2003, The Journal of Immunology.

[102]  D. Gabrilovich.  Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[103]  D. Gabrilovich,et al.  STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion1 , 2005, The Journal of Immunology.

[104]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[105]  H. Saji,et al.  Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[106]  H. Young,et al.  Immortalized Myeloid Suppressor Cells Trigger Apoptosis in Antigen-Activated T Lymphocytes1 , 2000, The Journal of Immunology.

[107]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[108]  A. Mantovani,et al.  The origin and function of tumor-associated macrophages. , 1992, Immunology today.

[109]  M. Colombo,et al.  IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice1 , 2003, The Journal of Immunology.

[110]  Yuan Zhang,et al.  CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. , 2006, Cancer research.

[111]  G. Kollias,et al.  Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. , 1999, Nature medicine.

[112]  L. Brys,et al.  Peroxisome proliferator-activated receptor γ (PPARγ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer , 2006 .

[113]  P. Sinha,et al.  Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. , 2005, Cancer research.

[114]  A. Yoshimura,et al.  Signal transduction of inflammatory cytokines and tumor development , 2006, Cancer science.

[115]  G. Trinchieri,et al.  Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. , 2005, Cancer research.

[116]  L. Coussens,et al.  MMP9 potentiates pulmonary metastasis formation. , 2002, Cancer cell.

[117]  Seiya Kato,et al.  IFNγ-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice , 2006, The Journal of experimental medicine.

[118]  Paolo Serafini,et al.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.

[119]  N. Martinet,et al.  Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. , 2002, The Journal of laboratory and clinical medicine.

[120]  A. Sica,et al.  A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter , 1995, The Journal of experimental medicine.

[121]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[122]  M. Colombo,et al.  Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.

[123]  P. Allavena,et al.  Identification of Biologically Active Chemokine Isoforms from Ascitic Fluid and Elevated Levels of CCL18/Pulmonary and Activation-regulated Chemokine in Ovarian Carcinoma* , 2002, The Journal of Biological Chemistry.

[124]  R. Greil,et al.  IL-4 inhibits the TNF-α induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-α to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses , 2006, Cancer Immunology, Immunotherapy.

[125]  A. Harris,et al.  Secretion of epidermal growth factor by macrophages associated with breast carcinoma , 1993, The Lancet.

[126]  B. Baban,et al.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.

[127]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .

[128]  V. Bronte,et al.  High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells , 2004, Cancer Research.

[129]  J. O’Shea,et al.  A new modality for immunosuppression: targeting the JAK/STAT pathway , 2004, Nature Reviews Drug Discovery.

[130]  J. Berzofsky,et al.  Resistance to Metastatic Disease in STAT6-Deficient Mice Requires Hemopoietic and Nonhemopoietic Cells and Is IFN-γ Dependent1 , 2002, The Journal of Immunology.

[131]  A. Sica,et al.  A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). , 2006, Blood.